NO20074404L - Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid - Google Patents
Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acidInfo
- Publication number
- NO20074404L NO20074404L NO20074404A NO20074404A NO20074404L NO 20074404 L NO20074404 L NO 20074404L NO 20074404 A NO20074404 A NO 20074404A NO 20074404 A NO20074404 A NO 20074404A NO 20074404 L NO20074404 L NO 20074404L
- Authority
- NO
- Norway
- Prior art keywords
- microcrystalline
- quinolin
- indol
- ylmethyl
- fluoro
- Prior art date
Links
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 title 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504150.4A GB0504150D0 (en) | 2005-03-01 | 2005-03-01 | Microcrystalline material |
| PCT/GB2006/000704 WO2006092579A1 (fr) | 2005-03-01 | 2006-03-01 | Acide (5-fluoro-2-méthyl-3-quinoline-2-ylméthylindol-1-yl) acétique microcristallin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074404L true NO20074404L (no) | 2007-10-25 |
Family
ID=34430394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074404A NO20074404L (no) | 2005-03-01 | 2007-08-29 | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100041699A1 (fr) |
| EP (1) | EP1856094A1 (fr) |
| JP (1) | JP2008531668A (fr) |
| KR (1) | KR20070107184A (fr) |
| CN (1) | CN101133047A (fr) |
| AU (1) | AU2006219689A1 (fr) |
| BR (1) | BRPI0607423A2 (fr) |
| CA (1) | CA2600891A1 (fr) |
| GB (1) | GB0504150D0 (fr) |
| IL (1) | IL185453A0 (fr) |
| MX (1) | MX2007010588A (fr) |
| NO (1) | NO20074404L (fr) |
| NZ (1) | NZ561246A (fr) |
| RU (1) | RU2007132203A (fr) |
| WO (1) | WO2006092579A1 (fr) |
| ZA (1) | ZA200707233B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| AU2007279079A1 (en) * | 2006-07-22 | 2008-01-31 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CN101500996B (zh) | 2006-08-07 | 2012-07-04 | 埃科特莱茵药品有限公司 | (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物 |
| WO2009061730A2 (fr) | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | Acide phénoxyphénylacétique substitué par hétéroaryle en position 4 |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| HRP20140045T1 (hr) | 2008-01-18 | 2014-02-14 | Atopix Therapeutics Limited | Spojevi koji imaju antagonistiäśku aktivnost na crth2 |
| WO2009093029A1 (fr) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Composés présentant une activité antagoniste de crth2 |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| JP5069804B2 (ja) * | 2010-03-01 | 2012-11-07 | 隆雄 篠澤 | 筋萎縮性側索硬化症（ａｌｓ）の患者の進行度を判定し進行のモニターを行う方法 |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| EP2457900A1 (fr) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2 |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| WO2012140612A1 (fr) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2 |
| GB201121557D0 (en) * | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| UA117780C2 (uk) | 2014-03-17 | 2018-09-25 | Ідорсія Фармасьютікалз Лтд | Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2 |
| RU2016140708A (ru) | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| UA123156C2 (uk) | 2015-09-15 | 2021-02-24 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ |
| EP3902795A1 (fr) | 2018-12-27 | 2021-11-03 | Chiesi Farmaceutici S.p.A. | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
| CN113975272A (zh) * | 2021-11-29 | 2022-01-28 | 西安交通大学 | 吲哚乙酸（iaa）在制备预防或治疗炎症性肠病药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
-
2005
- 2005-03-01 GB GBGB0504150.4A patent/GB0504150D0/en not_active Ceased
-
2006
- 2006-03-01 WO PCT/GB2006/000704 patent/WO2006092579A1/fr not_active Ceased
- 2006-03-01 AU AU2006219689A patent/AU2006219689A1/en not_active Abandoned
- 2006-03-01 BR BRPI0607423A patent/BRPI0607423A2/pt not_active IP Right Cessation
- 2006-03-01 NZ NZ561246A patent/NZ561246A/en unknown
- 2006-03-01 CN CNA2006800067626A patent/CN101133047A/zh active Pending
- 2006-03-01 EP EP06709928A patent/EP1856094A1/fr not_active Withdrawn
- 2006-03-01 KR KR1020077022388A patent/KR20070107184A/ko not_active Withdrawn
- 2006-03-01 MX MX2007010588A patent/MX2007010588A/es not_active Application Discontinuation
- 2006-03-01 RU RU2007132203/04A patent/RU2007132203A/ru unknown
- 2006-03-01 CA CA002600891A patent/CA2600891A1/fr not_active Abandoned
- 2006-03-01 JP JP2007557577A patent/JP2008531668A/ja active Pending
- 2006-03-01 US US11/817,399 patent/US20100041699A1/en not_active Abandoned
-
2007
- 2007-08-22 IL IL185453A patent/IL185453A0/en unknown
- 2007-08-27 ZA ZA200707233A patent/ZA200707233B/xx unknown
- 2007-08-29 NO NO20074404A patent/NO20074404L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2600891A1 (fr) | 2006-09-08 |
| GB0504150D0 (en) | 2005-04-06 |
| AU2006219689A1 (en) | 2006-09-08 |
| ZA200707233B (en) | 2008-11-26 |
| JP2008531668A (ja) | 2008-08-14 |
| MX2007010588A (es) | 2007-10-23 |
| EP1856094A1 (fr) | 2007-11-21 |
| KR20070107184A (ko) | 2007-11-06 |
| BRPI0607423A2 (pt) | 2016-11-08 |
| WO2006092579A1 (fr) | 2006-09-08 |
| AU2006219689A2 (en) | 2006-09-08 |
| NZ561246A (en) | 2009-09-25 |
| IL185453A0 (en) | 2008-01-06 |
| RU2007132203A (ru) | 2009-04-10 |
| CN101133047A (zh) | 2008-02-27 |
| US20100041699A1 (en) | 2010-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074404L (no) | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid | |
| TNSN07325A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
| CL2008001896A1 (es) | 3-dihalometil-1-metil-1h-pirazol-4-carbaldehidos; su proceso de preparacion usando un intermediario de hidrazona, que reacciona con un agente de vilsmeier; y el derivado de hidrazona usado. | |
| NO20080784L (no) | Histondeacetylaseinhibitorer | |
| EA200801381A1 (ru) | Производные пиримидина | |
| TNSN07463A1 (en) | Process for the synthesis of organic compounds | |
| NO20053340D0 (no) | Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1). | |
| CY1111151T1 (el) | Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος | |
| CR9369A (es) | Compuestos de peridil acido acetico | |
| UA102817C2 (ru) | Способ синтеза агомелатина | |
| EA200901563A1 (ru) | Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
| NO20070379L (no) | Kjemiske forbindelser | |
| MX2009004154A (es) | Purinas como inhibidores de pkc-theta. | |
| CL2012000114A1 (es) | Proceso para la preparacion de compuestos derivados de 5-amino-benzonorbornadieno donde se hacer reaccionar un compuesto de 5-halo-benzonorbornadieno con una bencilamina en prensecia de un catalizador de paladio. | |
| NO20070564L (no) | Kinoliner uten tiazolinonsubstituenter. | |
| NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
| NO20081621L (no) | Tetrahydrokinoliner, syntese og intermediater | |
| NO20071012L (no) | Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat | |
| NO20080468L (no) | Diazepinokinoliner, synteser av disse samt intermediater | |
| NO20075618L (no) | Novel compounds as GLP-1 Agonists | |
| TW200640912A (en) | Novel processes for the preparation of a 2H-chromene | |
| AR064306A1 (es) | Antagonistas del receptor de angiotensina ii | |
| NO20074259L (no) | Fremgangsmate for fremstilling av substituerte benzoksazolforbindelser | |
| NO20072551L (no) | Fremgangsmate for fremstilling av purinforbindelser | |
| DK1877370T3 (da) | Fremgangsmåde til fremstilling af hydrazon-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |